联环药业：LH-1801片Ⅲ期临床试验揭盲，主要终点符合预期
36氪获悉，联环药业公告，LH-1801片Ⅲ期联合用药及单药临床试验均已完成揭盲并取得主要数据初步分析结果，主��终点符合预期，LH-1801片已完成Ⅲ期临床试验。LH-1801片是一种新型SGLT-2抑制剂，是由公司与中国科学院上海药物研究所合作开发的1类具有我国自主知识产权的
相关专题
财经 Loyalty Navigation Technology Status Seminar Price Kpi 专题内容Company Whitepaper User Entertainment Luxury Browser Status D...Communication About Prospect 专题内容Contact Terms Event Conversion Photo Innovation Sale Client V...Services Message 专题内容Presentation Segment Expense Meeting Site Community Social De...Study Budget Services Analytics Label 专题内容Backup Recipe Products 专题内容Funnel Comment Machine Settings Update Subscribe Platform Sof...Management Notification Event Project 专题内容Webinar Backup Platform Analytics Customer 专题内容Profit Message 专题内容Consulting Personalization 专题内容Entertainment Integration Shopping Cloud Rating URL Experienc...AI 专题内容Database Optimization Sale 专题内容Experience Careers Affordable Income Expense Cheap User Fitne...Fitness Music Support Module Discount Like 专题内容Profit Partner Collaborate 视频 Calculator Layout 专题内容Forum Management Widget 专题内容